UNASSIGNED: Patients with ICD diagnoses M33.1, M33.2, M33.9, or M609 who (1) had been tested with Euroline blot assay for myositis autoantibodies and (2) met the classification criteria of definite/probable polymyositis (PM) or dermatomyositis (DM), anti-synthetase syndrome (ASS), or inclusion body myositis (IBM) were included. Medical journals were retrospectively examined with respect to clinical disease features.
UNASSIGNED: Seventy patients (median age 58 years; 66% females) were included and represented the following diagnosis: PM (n = 23), DM (n = 21), ASS (n = 23), and IBM (n = 3). Most of the patients (87%) presented a muscle biopsy indicative of myositis. The presence of autoantibodies was as follows: myositis-specific antibodies, MSA (n = 53), myositis-associated antibodies, MAA (n = 33), both MSA + MAA (n = 24), MSA only (n = 29), MAA only (n = 9), no MSA, or MAA (n = 8). Anti-Jo-1 was the most common MSA (19%), whereas the most common MAA was anti-Ro/SSA52 (31%). We observed a significant association between antibody patterns and lung disease. In our cohort, 47% of the patients in the whole study group, 86% of patients with anti-SSA52, and 100% with anti-Jo-1 had pulmonary involvement. Patients with both MSA and MAA had a higher incidence of lung disease and decreased CO-diffusion capacity. This was especially prominent in anti-Ro/SSA52-positive patients. Interestingly, none of the patients suffered from lung disease if only antibodies against Mi-2α, Mi-2β, NXP2, HMGCR, and TIF1γ were present or no MSA/MAA were detected.
UNASSIGNED: The simultaneous presence of both MAA and MSA indicates an increased risk of lung involvement in patients with inflammatory myopathies. The presence of any MAA, and especially anti-Ro/SSA52, is associated with more severe pulmonary disease. Our data suggest that MAA antibodies might be relevant markers for early detection and treatment of lung involvement in IIM.
■ICD诊断为M33.1,M33.2,M33.9或M609的患者(1)已通过Euroline印迹测定法检测肌炎自身抗体,并且(2)符合明确/可能的多发性肌炎(PM)或皮肌炎(DM)的分类标准,抗合成酶综合征(ASS),或包涵体肌炎(IBM)被包括在内。对医学期刊的临床疾病特征进行了回顾性检查。
■包括70例患者(中位年龄58岁;66%为女性),并代表以下诊断:PM(n=23),DM(n=21),ASS(n=23),和IBM(n=3)。大多数患者(87%)表现为肌炎的肌肉活检。自身抗体的存在如下:肌炎特异性抗体,MSA(n=53),肌炎相关抗体,MAA(n=33),MSA+MAA(n=24),仅MSA(n=29),仅MAA(n=9),没有MSA,或MAA(n=8)。Anti-Jo-1是最常见的MSA(19%),而最常见的MAA是抗Ro/SSA52(31%)。我们观察到抗体模式与肺部疾病之间存在显着关联。在我们的队列中,整个研究组中47%的患者,86%的抗SSA52患者和100%的抗Jo-1患者肺部受累。同时患有MSA和MAA的患者肺部疾病的发生率更高,CO扩散能力降低。这在抗Ro/SSA52阳性患者中尤其突出。有趣的是,如果仅针对Mi-2α的抗体,则没有患者患有肺部疾病,Mi-2β,NXP2,HMGCR,和TIF1γ存在或未检测到MSA/MAA。
■同时存在MAA和MSA表明炎性肌病患者肺部受累的风险增加。任何MAA的存在,尤其是抗Ro/SSA52与更严重的肺部疾病相关。我们的数据表明,MAA抗体可能是早期发现和治疗IIM肺部受累的相关标志物。